BeyondSpring Inc. Ordinary Shares (BYSI)

FairStock Score: 17/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach BeyondSpring as a Graham-style analyst: no revenue, no earnings, and no conventional margin of safety in the accounts. It is a clinical-stage biotech with 44 employees, built around Plinabulin, which has completed Phase III trials in non-small cell lung cancer, and a TPD platform. In the filed figures, revenue is N/A in every period shown. Net losses have narrowed: -$21.0M in fiscal 2023, -$11.1M in fiscal 2024, and -$1.0M in fiscal 2025, according to the 10-Ks. In fiscal Q2 2026, the quarter ended 2026-06-30, the net loss was -$849,000. That is progress, but it is still red ink. At the close on 2026-10-13, the price was $0.61 and market cap $25.0M. FairStock calculations show a P/E of -3.37, FCF yield of -67.1% on trailing free cash flow of -$16.7M, Piotroski F-Score of 2/9, Altman Z-Score of -39.49, and a FairStock Score of 17/100. Those are not marks of a fortress; they suggest dependence on external capital and clinical success. The 52-week range is $0.57-$2.44, so the shares are near the low. A beta of -0.21 is unusual but creates no durable competitive moat. The pipeline is interesting, but I cannot underwrite a drug. Without revenue or profit, I have no reliable earnings power to value. The price is low, but the business is not yet proven. Narrowing losses are welcome, yet I would need commercial validation or cash self-sufficiency before calling this a sound value.

In plain English: BeyondSpring is a small medical research company working on cancer and immune therapies. It has no reported revenue and has lost money every year, though the losses have gotten smaller recently. The stock price is very low, but because there are no profits or sales, the price is not clearly cheap on the numbers shown; it mostly reflects hope that its drug research will succeed.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer